AMOYTOP(SH:688278) Zheng Quan Shi Bao·2026-01-19 18:08Core Viewpoint - The company, Teva Biopharma, is a leading enterprise in the field of PEGylated protein long-acting drugs in China, focusing on innovative research and development during the 14th Five-Year Plan period, achieving breakthroughs in liver disease treatment and children's growth [2][3]. Financial Performance - From 2021 to 2024, Teva Biopharma's revenue is projected to grow from 1.132 billion yuan to 2.817 billion yuan, with a compound annual growth rate (CAGR) exceeding 35% [2]. - Net profit is expected to increase from 181 million yuan to 828 million yuan, with a CAGR of 66%, positioning the company among the top performers in the biopharmaceutical industry [2]. Research and Development Focus - The company maintains high levels of R&D investment, exploring multi-platform technologies and collaborative approaches to address disease challenges, aiming to provide more treatment options for patients [2]. - In the liver disease treatment sector, the company is focused on clinical cures for hepatitis B, with its core product, Pegbinterferon (PEGylated interferon α-2b injection), set to receive approval for a new indication in October 2025 [2]. Product Innovations - The clinical data indicates that the combination therapy can achieve HBsAg seroconversion in 31.4% of patients, offering new hope for approximately 75 million chronic hepatitis B patients in China [2]. - In the children's growth sector, the innovative drug Yipeisheng (Yipei growth hormone injection) is expected to be approved in May 2025, featuring a unique Y-type 40kD PEGylation technology that allows for weekly administration, significantly reducing injection frequency [3]. Market Impact - The price of the 5 mg Yipeisheng injection will decrease from 1,798 yuan to 853.2 yuan, a reduction of about 53%, making treatment more affordable for families [3]. - The company has established an innovative platform centered on PEGylated long-acting drugs, with three class 1 innovative drugs launched, continuously enhancing its product matrix [3]. Future Outlook - Looking ahead to the next five years, the company aims to focus on unmet clinical needs for R&D innovation, providing high-quality products and services for human health [3]. - The company plans to strengthen collaboration with domestic and international partners to promote high-quality development in the biopharmaceutical industry [3].